Successful Treatment of Highly Resistant Trichomoniasis with Tinidazole and Paromomycin Regimen after Boric Acid Failure.

Sex Transm DisJul 30, 2026 (epub)

Karley Dutra, Paul Nyirjesy

✦ AI-curated · Sources linked

Case in brief

Two patients with Trichomonas vaginalis infection had persistent disease despite high-dose tinidazole and boric acid. Both were subsequently treated successfully with a regimen combining tinidazole and paromomycin. The report describes these treatment failures and outcomes in the context of increasing metronidazole and tinidazole resistance; the abstract does not provide further clinical findings or treatment details.

What made this case unusual

Both patients had failed high-dose tinidazole and boric acid before responding to the tinidazole–paromomycin regimen.

Diagnostic / clinical pearl

For persistent T. vaginalis infection after high-dose tinidazole and boric acid, this report describes successful treatment with tinidazole plus paromomycin.

Why it matters

Paromomycin cream with high-dose tinidazole may be limited by vulvovaginal ulceration, an adverse effect relevant to considering this regimen.

Source

Published in Sex Transm Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.